SCHEDULE 13G/A: Wellington Management Group Discloses 9.2% Stake in Kymera Therapeutics

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.2% in Kymera Therapeutics, Inc. as of March 31, 2025.

Summary

• Wellington Management Group LLP, along with its affiliates Wellington Group Holdings LLP, Wellington Investment Advisors Holdings LLP, and Wellington Management Company LLP, filed an Amendment No. 5 to Schedule 13G.
• The filing reports beneficial ownership of 5,996,873 shares of Kymera Therapeutics, Inc. Common Stock.
• This aggregate amount represents 9.2% of Kymera Therapeutics, Inc.'s outstanding common stock.
• The reporting persons hold no sole voting or dispositive power over these shares.
• Shared voting power is reported as 5,565,385 shares for the group (5,562,985 for Wellington Management Company LLP specifically).
• Shared dispositive power is reported as 5,996,873 shares for the group (5,839,304 for Wellington Management Company LLP specifically).
• The securities are owned of record by clients of Wellington Investment Advisers, who have the right to receive dividends or proceeds from the sale of such securities.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently lead to a positive or negative sentiment. It is a neutral, compliance-driven filing.

Future Outlook

NA

Industry Context

This filing is a routine disclosure by a large institutional investment manager, Wellington Management Group, indicating its significant passive stake in Kymera Therapeutics, a biotechnology company. Such disclosures provide transparency regarding major institutional holdings in publicly traded companies, which can be viewed as a vote of confidence by a sophisticated investor.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, potentially signaling confidence from a major investor.

Key Dates

Keywords

Kymera Therapeutics, Wellington Management Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Investment Management